Neurocrine Biosciences, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024. For the fourth quarter of 2024, net product sales reached $621.2 million, an increase from $507.2 million in the same period of 2023, representing 23% year-over-year growth. Full year 2024 net product sales for INGREZZA were $2.3 billion, up 26% from $1.86 billion in 2023.
The company reported GAAP net income of $103.1 million, or $1.00 diluted earnings per share, for Q4 2024, and $341.3 million, or $3.29 diluted earnings per share, for the full year 2024. As of December 31, 2024, Neurocrine maintained a strong liquidity position with $1,815.6 million in cash, cash equivalents, and marketable securities.
Neurocrine provided its financial guidance for 2025, projecting INGREZZA net product sales between $2.5 billion and $2.6 billion. The company also announced that CRENESSITY was approved and launched in the United States, and Phase 3 programs for osavampator in Major Depressive Disorder and NBI-'568 in Schizophrenia are initiating in the first half of 2025, signaling continued pipeline advancement and revenue diversification.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.